0 works0 citations0 h-index

M. Neubauer

Universität für Weiterbildung Krems(AT)Universitätsklinikum Krems(AT)Karl Landsteiner University of Health Sciences(AT)

Publications by Year

Research Areas

Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Lymphoma Diagnosis and Treatment, Lung Cancer Diagnosis and Treatment, Neuroendocrine Tumor Research Advances

Most-Cited Works

→ Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology(2011)79 cited
→ Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing ≥ 10% epidermal growth factor receptor (EGFr)(2006)65 cited
→ Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01–24/USO-023(2007)60 cited
→ Risk profile analysis and complications after surgery for autoimmune thyroid disease(2018)34 cited
→ Early response monitoring during [177Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study(2023)29 cited

→ Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin’s lymphoma (NHL). A multi- center trial by the Austrian Working Group For Medical Tumor Therapy(1997)

27 cited

→ Efficacy and toxicity of 2-chlorodeoxyadenosine (cladribine)—2h infusion for 5 days—as first-line treatment for advanced low grade non-Hodgkin’s lymphoma(1998)22 cited

→ Phase II study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced non-small cell lung cancer (NSCLC)(2007)19 cited

→ Phase III study of cisplatin (P) plus etoposide (E) with concurrent chest radiation (XRT) followed by docetaxel (D) vs. observation in patients (pts) with stage III non-small cell lung cancer (NSCLC): An interim toxicity analysis of consolidation therapy(2006)16 cited

→ 806 Phase 2 study of first line chemotherapy using CT-2103 (XYOTAX) in patients with non-small-cell lung cancer who are > 69 years of age or who have performance status (PS) = 2(2003)13 cited